Making any protein possible ENGINEERING FIT-FOR-PURPOSE BIOTHERAPEUTICS Rooted in protein modeling and structure-guided engineering, our platforms make any protein possible, from cytotoxic anti-tumor biologics to antibody drug conjugates and immuno-oncology therapies. Building better biologicsTM RATIONALLY DESIGNED. ELEGANTLY SIMPLE. Fully integrated protein engineering technologies that make any protein possible. EXPLORE PLATFORMS AZYMETRIC™ Build the Best Bispecifics by creating tailored multifunctional therapeutics that enable enhanced efficacy and new biological approaches for treating diseases ZYMELINK™ Enhance Therapeutic Response with a modular suite of proprietary cytotoxins (cell-killing compounds), stable linkers, and conjugation technologies. A broader window of opportunity. Deliver potent cell-killing compounds specifically to diseased target cells with optimal safety and efficacy. ZymeLink™, a next-generation antibody drug conjugate (ADC) platform, is a suite of proprietary cytotoxins (cell-killing compounds), stable linkers, and conjugation technologies. ZymeLink™ is compatible with traditional antibodies, proteins, and the Azymetric™ bispecific antibody platform, creating multifunctional therapeutics designed to overcome the limitations of existing ADCs. HOW WE DIFFER Develop next-generation antibody drug conjugates with broad therapeutic windows. ZymeLink™ antibody drug conjugates are designed to: Closely resemble natural antibodies with improved pharmacokinetics, stability, and cytotoxin exposure over alternative ADC technologies Exhibit increased tolerability Demonstrate a broad therapeutic window, a key competitive advantage over existing ADC platforms HOW IT WORKS The ZymeLink ADC platform is designed to combine the specificity of traditional and bispecific antibodies with the strength of potent cytotoxins (cell-killing compounds) to treat cancer and other diseases. Zymeworks is developing diverse classes of proprietary cytotoxins with potent anti-tumor activity against a broad range of cancer cell types. Innovative, stable linkers chemically attach cytotoxins to a variety of targeted therapeutics, including traditional antibodies, proteins, and the Azymetric™ bispecific antibody platform. Each linker is tailored to a specific cytotoxin to enable optimal safety and efficacy of the ADC. Together, the ZymeLink™ ADC platform and Azymetric™ bispecific antibody platform are designed for the development of best-in-class, life-changing medicines for patients EFECT™ Customize & Optimize Immune Response using precise antibody Fc modifications that tailor the antibody-mediated immune response PROTECT™ Tumor‑Specific Immune Co‑stimulation in a single, transferable, conditionally active design TECHNOLOGY Azymetric™ ZymeLink™ EFECT™ ProTECT™ Science PIPELINE Zanidatamab ZW49 Preclinical Candidates Partnerships Publications For Patients INVESTORS Stock Info News Releases Events & Presentations Financials Governance CORPORATE Leadership Board of Directors Careers Legal Privacy Contact Twitter LinkedIn